Publications: I. Nestorov
| Title | Year | Citations | Score |
|---|---|---|---|
|
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease
The journal of prevention of Alzheimer's disease, 2022 View Details |
2022 | 1051 | 100.0% |
|
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
New England Journal of Medicine, 2020 View Details |
2020 | 411 | 99.8% |
|
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
Blood, 2014 View Details |
2014 | 438 | 99.7% |
|
Whole Body Pharmacokinetic Models
Clinical Pharmacokinetics, 2003 View Details |
2003 | 281 | 98.1% |
|
Whole-body physiologically based pharmacokinetic models
Expert Opinion on Drug Metabolism & Toxicology, 2007 View Details |
2007 | 191 | 97.3% |
|
Clinical pharmacokinetics of TNF antagonists: how do they differ?
Seminars in Arthritis & Rheumatism, 2005 View Details |
2005 | 195 | 97.0% |
|
A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
Journal of clinical pharmacology, 2012 View Details |
2012 | 118 | 96.4% |
|
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Neurology, 2017 View Details |
2017 | 78 | 95.3% |
|
An Exploratory Dose-Escalating Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Atacicept in Patients with Systemic Lupus Erythematosus
Lupus, 2009 View Details |
2009 | 118 | 95.2% |
|
Lumping of Whole-Body Physiologically Based Pharmacokinetic Models
Journal of pharmacokinetics and biopharmaceutics, 1998 View Details |
1998 | 137 | 94.8% |
|
Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration
Fluids and Barriers of the CNS, 2018 View Details |
2018 | 63 | 94.1% |
|
Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease
Alzheimer's & Dementia, 2020 View Details |
2020 | 54 | 93.8% |
|
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration
Journal of Pharmacokinetics and Pharmacodynamics, 2021 View Details |
2021 | 42 | 93.3% |
|
Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels
Journal of Thrombosis and Haemostasis, 2014 View Details |
2014 | 69 | 93.2% |
|
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis
Clinical pharmacology and therapy, 2003 View Details |
2003 | 110 | 92.5% |
|
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
British Journal of Cancer, 2009 View Details |
2009 | 80 | 91.9% |
|
Clinical pharmacokinetics of tumor necrosis factor antagonists.
Journal of Rheumatology Supplement, 2005 View Details |
2005 | 83 | 90.4% |
|
Population Pharmacokinetic Analysis and Simulation of the Time‐Concentration Profile of Etanercept in Pediatric Patients With Juvenile Rheumatoid Arthritis
Journal of clinical pharmacology, 2005 View Details |
2005 | 82 | 90.3% |
|
Quantitative Structure-Pharmacokinetics Relationships: I. Development of a Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat
Journal of pharmacokinetics and biopharmaceutics, 1997 View Details |
1997 | 77 | 89.6% |
|
The pharmacokinetics of etanercept in patients with end‐stage renal disease on haemodialysis
The Journal of pharmacy and pharmacology, 2005 View Details |
2005 | 76 | 89.4% |
|
Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.
Clinical Therapeutics, 2013 View Details |
2013 | 51 | 89.1% |
|
Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
Clinical Pharmacokinetics, 2014 View Details |
2014 | 48 | 89.0% |
|
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
European Journal of Clinical Pharmacology, 2007 View Details |
2007 | 66 | 88.6% |
|
Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis
Journal of clinical pharmacology, 2008 View Details |
2008 | 58 | 87.6% |
|
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
Journal of clinical pharmacology, 2017 View Details |
2017 | 38 | 87.1% |
|
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab
The journal of prevention of Alzheimer's disease, 2023 View Details |
2023 | 15 | 85.1% |
|
Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study
Journal of Pharmacokinetics and Pharmacodynamics, 2006 View Details |
2006 | 52 | 84.6% |
|
Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease
CPT: Pharmacometrics & Systems Pharmacology, 2021 View Details |
2021 | 22 | 83.8% |
|
PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis
Journal of Interferon and Cytokine Research, 2010 View Details |
2010 | 41 | 83.8% |
|
Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
British Journal of Clinical Pharmacology, 2006 View Details |
2006 | 49 | 83.7% |
|
Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma
Clinical Cancer Research, 2008 View Details |
2008 | 42 | 82.8% |
|
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
British Journal of Clinical Pharmacology, 2016 View Details |
2016 | 29 | 82.3% |
|
A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
CPT: Pharmacometrics & Systems Pharmacology, 2018 View Details |
2018 | 27 | 82.3% |
|
In Vivo Intrathecal Tracer Dispersion in Cynomolgus Monkey Validates Wide Biodistribution Along Neuraxis
IEEE Transactions on Biomedical Engineering, 2020 View Details |
2020 | 24 | 82.2% |
|
Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen.
Neuromuscular Disorders, 2021 View Details |
2021 | 20 | 81.9% |
|
Fuzzy Simulation of Pharmacokinetic Models: Case Study of Whole Body Physiologically Based Model of Diazepam
Journal of Pharmacokinetics and Pharmacodynamics, 2004 View Details |
2004 | 43 | 80.8% |
|
Sensitivity Analysis of Pharmacokinetic and Pharmacodynamic Systems: I. A Structural Approach to Sensitivity Analysis of Physiologically Based Pharmacokinetic Models
Journal of pharmacokinetics and biopharmaceutics, 1999 View Details |
1999 | 43 | 80.2% |
|
Modeling and Simulation for Clinical Trial Design Involving a Categorical Response: A Phase II Case Study with Naratriptan
Pharmaceutical Research, 2001 View Details |
2001 | 44 | 80.2% |
|
In Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon β-1a
Journal of Pharmacology and Experimental Therapeutics, 2011 View Details |
2011 | 31 | 79.7% |
|
Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies
mAbs, 2016 View Details |
2016 | 24 | 78.8% |
|
Tissue Distribution and Physiologically Based Pharmacokinetics of Antisense Phosphorothioate Oligonucleotide ISIS 1082 in Rat
Antisense and Nucleic Acid Drug Development, 2001 View Details |
2001 | 40 | 78.5% |
|
Development of a Whole Body Physiologically Based Model to Characterise the Pharmacokinetics of Benzodiazepines. 1: Estimation of Rat Tissue-Plasma Partition Ratios
Journal of Pharmacokinetics and Pharmacodynamics, 2004 View Details |
2004 | 35 | 77.2% |
|
Physiologically Based Pharmacokinetic Modeling of a Homologous Series of Barbiturates in the Rat: A Sensitivity Analysis
Journal of pharmacokinetics and biopharmaceutics, 1997 View Details |
1997 | 33 | 76.5% |
|
Empirical versus mechanistic modelling: Comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates
AAPS PharmSci, 1999 View Details |
1999 | 35 | 76.5% |
|
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
British Journal of Clinical Pharmacology, 2015 View Details |
2015 | 21 | 75.2% |
|
Population Pharmacokinetic Modeling of Subcutaneously Administered Etanercept in Patients with Psoriasis
Journal of Pharmacokinetics and Pharmacodynamics, 2004 View Details |
2004 | 30 | 74.4% |
|
Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
CPT: Pharmacometrics & Systems Pharmacology, 2022 View Details |
2022 | 12 | 74.4% |
|
Quantitative Structure–Pharmacokinetics Relationships: II. A Mechanistically Based Model to Evaluate the Relationship Between Tissue Distribution Parameters and Compound Lipophilicity
Journal of pharmacokinetics and biopharmaceutics, 1998 View Details |
1998 | 29 | 73.6% |
|
Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data.
Drug Metabolism And Disposition, 2002 View Details |
2002 | 29 | 72.7% |
|
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials
Clinical Pharmacokinetics, 2016 View Details |
2016 | 17 | 71.7% |
|
Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.
British Journal of Clinical Pharmacology, 2016 View Details |
2016 | 16 | 70.4% |
|
Uncertainty Analysis in Pharmacokinetics and Pharmacodynamics: Application to Naratriptan
Pharmaceutical Research, 2005 View Details |
2005 | 20 | 67.2% |
|
An age‐dependent mathematical model of neurofilament trafficking in healthy conditions
CPT: Pharmacometrics & Systems Pharmacology, 2022 View Details |
2022 | 9 | 66.4% |
|
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials
Journal of Pharmacokinetics and Pharmacodynamics, 2023 View Details |
2023 | 7 | 65.5% |
|
A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans
Journal of Pharmacokinetics and Pharmacodynamics, 2018 View Details |
2018 | 12 | 64.6% |
|
Evaluation of Potential Drug–Drug Interaction Between Delayed‐Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women
Clinical pharmacology in drug development, 2017 View Details |
2017 | 12 | 63.8% |
|
A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
CPT: Pharmacometrics & Systems Pharmacology, 2022 View Details |
2022 | 8 | 62.9% |
|
Modeling the Exposure‐Response Relationship of Etanercept in the Treatment of Patients With Chronic Moderate to Severe Plaque Psoriasis
Journal of clinical pharmacology, 2007 View Details |
2007 | 14 | 61.4% |
|
In Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon (cid:1) -1a
2011 View Details |
2011 | 12 | 61.2% |
|
A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus
Journal of Pharmacokinetics and Pharmacodynamics, 2020 View Details |
2020 | 9 | 58.7% |
|
Simulating pharmacokinetic and pharmacodynamic fuzzy-parameterized models: a comparison of numerical methods
Journal of Pharmacokinetics and Pharmacodynamics, 2007 View Details |
2007 | 12 | 58.3% |
|
Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration
Fluids and Barriers of the CNS, 2018 View Details |
2018 | 8 | 55.1% |
|
Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis
Journal of Pharmacokinetics and Pharmacodynamics, 2017 View Details |
2017 | 8 | 54.4% |
|
Tofersen in adults with SOD1-ALS: phase 3 VALOR trial and open-label extension results
Journal of Neurology Neurosurgery & Psychiatry, 2022 View Details |
2022 | 6 | 54.0% |
|
Safety, Tolerability, and Pharmacokinetics of BG-12 Administered with and without Aspirin: Key Findings from a Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Volunteers (P04.136)
2012 View Details |
2012 | 8 | 53.5% |
|
Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
Journal of clinical pharmacology, 2017 View Details |
2017 | 7 | 51.3% |
|
Physiologically Based Pharmacokinetic Modeling of Drug Disposition in Rat and Human: A Fuzzy Arithmetic Approach
Pharmaceutical Research, 2008 View Details |
2008 | 8 | 51.1% |
|
Fuzzy Least Squares for Identification of Individual Pharmacokinetic Parameters
IEEE Transactions on Biomedical Engineering, 2009 View Details |
2009 | 7 | 48.8% |
|
Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
Journal of clinical pharmacology, 2014 View Details |
2014 | 6 | 47.9% |
|
Highlights From a Recent BIO Survey on Therapeutic Protein‐Drug Interactions
Journal of clinical pharmacology, 2012 View Details |
2012 | 6 | 47.1% |
|
Clinical Pharmacokinetics of Tonapofylline: Evaluation of Dose Proportionality, Oral Bioavailability, and Gender and Food Effects in Healthy Human Subjects
Journal of clinical pharmacology, 2011 View Details |
2011 | 5 | 42.3% |
|
Comparative pharmacokinetics of etanercept in patients with psoriasis or rheumatoid arthritis
2004 View Details |
2004 | 6 | 41.4% |
|
A fuzzy physiologically based pharmacokinetic modeling framework to predict drug disposition in humans
Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006 View Details |
2006 | 4 | 34.2% |
|
A Time‐to‐Event Exposure‐Response Model for Amyloid‐Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease
Journal of clinical pharmacology, 2022 View Details |
2022 | 3 | 32.6% |
|
Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients
Journal of Pharmacokinetics and Pharmacodynamics, 2016 View Details |
2016 | 3 | 31.3% |
|
Tofersen, a SOD1 Antisense Oligonucleotide in Participants with ALS – Results From a Multiple Dose Study (657)
Neurology, 2020 View Details |
2020 | 3 | 29.9% |
|
Pharmacokinetics of etanercept, a TNF antagonist, in patients with psoriasis treated in two double-blind phase 3 trials
2004 View Details |
2004 | 3 | 26.1% |
|
CSS1-2 Pharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: Results from two Phase 1 clinical studiesPharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: Results from two Phase 1 clinical
2009 View Details |
2009 | 2 | 19.2% |
|
Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimerâ•Žs disease: Developments in clinical trials and cognitive assessment
2020 View Details |
2020 | 2 | 19.1% |
|
Prediction of in vivo performance of oral extended release (ER) formulations prior to clinical evolution: A case study for enteric coated polymeric beads formulation.
European journal of pharmaceutics and biopharmaceutics, 2020 View Details |
2020 | 2 | 19.1% |
|
Phase 1 Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma.
2006 View Details |
2006 | 2 | 17.9% |
|
Modeling of placebo drug effect using a population pharmacodynamic mixture model
2004 View Details |
2004 | 2 | 16.8% |
|
Accumulation profiles during quasi-uniform multiple dosing regimens
Journal of pharmacokinetics and biopharmaceutics, 1993 View Details |
1993 | 2 | 16.0% |
|
A WWW resource for physiologically based modelling in pharmacokinetics, pharmacodynamics, toxicology and risk assessment.
Medical informatics = Medecine et informatique, 1998 View Details |
1998 | 2 | 15.8% |
|
Empirical versus mechanistic modeling: Comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetics relationship
1999 View Details |
1999 | 2 | 15.6% |
|
Model-based Integration for Clinical Trial Simulation and Design: A Phase ll Case Study for Naratriptan
2003 View Details |
2003 | 1 | 0.0% |
|
A whole body physiologically based pharmacokinetic model for the distribution of barbiturates in rats
1996 View Details |
1996 | 1 | 0.0% |
|
Incorporating Variability and Uncertainty into the In Vitro - In Vivo Predictioon of Hepatic Clearance. Proc. 5th EUFEPS Conference: Optimising Drug Development: Fastracking into Human, Wiesbaden, Germany, December 1998
1998 View Details |
1998 | 1 | 0.0% |
|
Pharmacokinetics of etanercept in patients with psoriasis are similar after either intermittent or continuous treatment
2004 View Details |
2004 | 1 | 0.0% |
|
hemophilia A Phase 3 study of recombinant factor VIII Fc fusion protein in severe
2014 View Details |
2014 | 1 | 0.0% |
|
Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (P3.194)
2014 View Details |
2014 | 1 | 0.0% |
|
Erratum to: Quantitative Structure-Pharmacokinetics Relationships: I. Development of Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat
Journal of pharmacokinetics and biopharmaceutics, 1998 View Details |
1998 | 1 | 0.0% |
|
Corrigendum to 'Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen': Neuromuscular Disorders 31 (2021) 310-318/doi: 10.1016/j.nmd.2021.02.014.
Neuromuscular Disorders, 2022 View Details |
2022 | 1 | 0.0% |